Bristol-myers Squibb Stock News

Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio Presents at JPMorgan 40th Annual Healthcare Brokers Conference (Transcript)

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Century Therapeutics Inc (NASDAQ: IPSC) and Bristol Myers Squibb Co (NYSE: BMY) have announced a research collaboration and license agreement for up to four induced pluripotent stem cell (iPSC) p

Last month we discussed that there are good chances of a rise in Bristol Myers Squibb stock based on its historical performance. BMY stock is up 8% over the last month, primarily driven by increased i

Some of the world's biggest drugmakers have important dates with the FDA coming up soon.

REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ: BOLT ), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that the first patient has been dosed in a new combination arm of the ongoing multi-center, multi-dose Phase 1/2 clinical trial of BDC-1001. This arm is evaluating BDC-1001 in combination with Bristol Myers Squibb''s PD-1 checkpoint inhibitor OPDIVO® (nivolumab). In parallel, Bolt continues to advance the single-agent portion of the study, following the presentation of interim dose-escalation data at the European Society of Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2021. BDC-1001 is a HER2-targeting Boltbody immune-stimulating antibody conjugate (ISAC) (trastuzumab biosimilar conjugated to a toll-like receptor 7 and 8 agonist) in development for the treatment of patients with HER2-expressing solid tumors. "We are excited to evaluate BDC-1001 in combination with nivolumab, a leading PD-1 checkpoint inhibitor.

These seven pharmaceutical stocks could create lucrative opportunities in the new year The post 7 Pharmaceutical Stocks That Could Make You Rich appeared first on InvestorPlace. More From InvestorPlac

Bristol-Myers Squibb (NYSE:BMY) Is Paying Out A Larger Dividend Than Last Year Nasdaq

The Alzheimer's Disease treatment market is known for its vast potential given the fact that there are hardly any active drugs and therapies that produce any real improvements in patients' conditions.

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

The list includes Exxon Mobil, Philip Morris, Kellogg, Bristol Myers Squibb, 3M, Chevron, AbbVie, Gilead and Kinder Morgan.

Bristol Myers Squibb is rewarding its shareholders with a huge dividend hike and a massive share-buyback program.

Bristol Myers Squibb is rewarding its shareholders with a huge dividend hike and a massive share-buyback program.

The U.S. Food and Drug Administration recently acknowledged Bristol Myers Squibb''s application for deucravacitinib to treat moderate-to-severe psoriasis.